Drug Approval Package
  • Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

Drug Approval Package

  • Print
  • Share
  • E-mail

Prezista (darunavir) suspension, 100 mg/mL and tablets, 75 mg, 150 mg, 400 mg, and 600 mg
Company: Tibotec, Inc
Application No.: 202895
Approval Date: 12/16/2011

Persons with disabilities having problems accessing the PDF files below may call (301) 796-3634 for assistance.


Date created: September 6, 2012

Back to Top    Drugs@FDA

Vision impaired people having problems accessing certain pages of a PDF file may call (301) 796-3634 for assistance.

Note: Documents in PDF format require the Adobe Acrobat Reader®.